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Abstract
Purpose We examined the literature to elucidate the role of 18F-sodium fluoride (NaF)-PET in atherosclerosis.
Methods Following a systematic search of PubMed/MEDLINE, Embase, and Cochrane Library included articles underwent
subjective quality assessment with categories low, medium, and high. Of 2811 records, 1780 remained after removal of dupli-
cates. Screening by title and abstract left 41 potentially eligible full-text articles, of which 8 (about the aortic valve (n = 1), PET/
MRI feasibility (n = 1), aortic aneurysms (n = 1), or quantification methodology (n = 5)) were dismissed, leaving 33 published
2010–2012 (n = 6), 2013–2015 (n = 11), and 2016–2018 (n = 16) for analysis.
Results They focused on coronary (n = 8), carotid (n = 7), and femoral arteries (n = 1), thoracic aorta (n = 1), and infrarenal aorta (n =
1). The remaining 15 studies examinedmore than one arterial segment. The literature was heterogeneous: few studies were designed to
investigate atherosclerosis, 13 were retrospective, 9 applied both FDG and NaF as tracers, 24 NaF only. Subjective quality was low in
one, medium in 13, and high in 19 studies. The literature indicates that NaF is a very specific tracer that mimics active arterial wall
microcalcification, which is positively associated with cardiovascular risk. Arterial NaF uptake often presents before CT-calcification,
tends to decrease with increasing density of CT-calcification, and appears, rather than FDG-avid foci, to progress to CT-calcification. It
is mainly surface localized, increases with age with a wide scatter but without an obvious sex difference. NaF-avid microcalcification
can occur in fatty streaks, but the degree of progression to CT-calcification is unknown. It remains unknown whether medical therapy
influences microcalcification. The literature held no therapeutic or randomized controlled trials.
Conclusion The literature was heterogeneous and with few clear cut messages. NaF-PET is a new approach to detect and quantify
microcalcification in early-stage atherosclerosis. NaF uptake correlates with cardiovascular risk factors and appears to be a good
measure of the body’s atherosclerotic burden, potentially suited also for assessment of anti-atherosclerotic therapy.
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Introduction
Atherosclerosis is the world’s number one killer [1]. Most of
what we do against it are late occurring examinations and inter-
ventions that cannot effectively counteract the disease. What is
needed is the opposite, i.e., early diagnosis and grading of the
disease when it may still be susceptible to therapy. Molecular
in vivo imaging offers a new approach for studying early-stage
atherosclerosis by means of positron emission tomography
(PET) with two of the most widely used tracers, 18F-
fluorodeoxyglucose (FDG) and 18F-sodium fluoride (NaF),
markers of inflammation and ongoing ossification, respectively.
This is relevant because the two processes are closely associated
with the beginning of atherosclerosis and, thus, may provide a
window for the detection andmeasurement of early-stage athero-
sclerosis. FDG-PET imaging of atherosclerosis was introduced
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in 2001 [2, 3] and NaF-PET imaging approximately 10 years
later [4, 5]. While FDG-PET in atherosclerosis has been reported
in multiple publications, papers on NaF-PET imaging in athero-
sclerosis are less numerous. It has gradually become clear that
FDG uptake is not a straightforward marker of atherosclerosis,
whereas a number of observations point to NaF uptake as being
of potential clinical importance in atherosclerosis and a means of
obtaining a better understanding of its pathophysiologic mecha-
nism. The purpose of this review is to establish an overview of
published original research of clinical relevance about NaF-PET
in atherosclerosis and to examinewhat new information has been




The principles of a systematic review were used in an exten-
sive literature search of PubMed/MEDLINE, Embase, and
Cochrane Library to extract relevant peer-reviewed articles
on NaF-PET imaging in atherosclerosis. The search algo-
rithms were based on two combinations of search terms of
which every included article fell into at least one of these
combinations:
& Sodium fluoride AND atherosclerosis;
& Sodium fluoride AND (inflammation OR calcification)
AND (heart, arteries, OR aorta).
The search included articles on humans published in
English until December 31, 2018. The PICOS approach (pop-
ulation, intervention, comparison, outcome, study design) was
adopted [6] and comprised the following:
& Patients with any disease provided that NaF-PETwas used
for the detection of atherosclerosis
& Studies with focus on diagnostic performance, lesion de-
tection, qualitative evaluation, and feasibility
& Studies in which the stated primary aim was an evaluation
of atherosclerosis (no restriction on comparator methods if
any)
& No restriction on outcome measures
& No restriction on study design.
Records from the databases were transferred to the Endnote
reference tool to identify and remove duplicates and book
sections and screened by title and abstract according to strict
inclusion and exclusion criteria by one senior researcher (OG).
Exclusion criteria comprised the following: (a) articles outside
the scope of this review; (b) editorials, letters, comments, or
conference proceedings; and (c) case studies, studies with
other tracers than NaF, pure methodology studies, and review
articles. After removal of duplicates, one researcher, experi-
enced in clinical physiology and nuclear medicine and in car-
diology (PFHC), reviewed titles and abstracts and checked
their eligibility. This researcher also reviewed the full-text
versions of preliminarily included articles and decided in- or
exclusion. The selection procedure is illustrated in a Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) diagram [7] (Fig. 1), whichmirrors the result of the
conducted systematic literature search. Data were extracted
from each of the selected articles and grouped according to
number, age, and type of patients, prospective or retrospective
data collection, tracer (NaF only or NaF and FDG), and arter-
ies studied.
Quality assessment
Articles were categorized by a simple subjective a priori sys-
tem with three categories: low, medium, or high quality. The
system was similar to the QUADAS-2 criteria, which is based
on answers “yes,” “no,” or “unclear” to 14 specific questions
[8]. We evaluated based on each article’s ability to sufficiently
meet 12 quality items, which were given a grade, where 0 = no
fulfillment (complete lack of mention), 1 = partly fulfillment
(insufficient description or documentation), or 2 = complete or
nearly complete fulfillment (sufficient and relevant documen-
tation or argumentation). The items were as follows: (1) clin-
ical relevance, (2) aim(s), (3) hypothesis, (4) prospective or
retrospective data collection, (5) design and power, (6) de-
scription and size of material(s), (7) description and use of
method(s), (8) statistical analysis, (9) relevant presentation of
results, (10) interpretation, (11) limitations, (12) conclu-
sion(s). The maximum obtainable score was 12 × 2 = 24.
Quality was designated low (score 0–8), medium (score 9–
16), or high (score 17–24).
Results
Out of 2811 initial records, 41 full-text articles remained for
assessment of eligibility. Eight of these were dismissed for
reasons stated in Fig. 1. Thus, 33 human studies were included
in the qualitative synthesis of evidence, of which 6, 11, and 16
were published in 2010–2012, 2013–2015, and 2016–2018,
respectively. Eight papers dealt exclusively with the coronary
arteries [9–16] and seven solely with the carotid arteries [5,
17–22], while only one article focused on the thoracic aorta
[23], the infrarenal aorta [24], and the femoral arteries [25].
Four studies were looking on the whole heart and aorta
[26–29], whereas the remaining 11 articles focused also on
more than one part of the cardio-arterial system, i.e., coro-
naries, carotids, and aorta [30–32]; coronaries, aorta, and fem-
oral arteries [33]; coronaries and carotids [34]; carotid, aorta,
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iliac, and femoral arteries [4, 35]; carotid, aorta, femoral arter-
ies [36]; carotid, aorta, iliac [37]; carotid, subclavian, iliac,
whole aorta [38]; and, finally, aorta and iliac arteries [39].
In 24 articles, NaF was the only PET tracer, whereas 9
compared NaF with FDG in the same patients [9, 10, 19, 21,
23, 30, 34, 36, 37]. Thirteen articles were retrospective anal-
yses of PET scans performed for other purposes, typically
search for metastases in cancer patients, whereas 20 papers
described prospectively collected materials, but seldom in a
design suited to answer a specific hypothesis about atheroscle-
rosis. Eight articles reported data from ≤ 25 patients (range 4–
25), while 25 papers included results from 26–409 subjects or
patients. According to our subjective quality system, one
study was of low quality (score = 7), 14 of medium (score
range 11–16), and 18 of high quality (score range 17–23).
Below (and in Tables 1, 2, 3, and 4, Supplementary
material) the literature content is summarized in 6 sections,
each comprising results from some of the 33 included articles
illustrating:
– disease mechanisms and targeting [14, 15, 17, 22, 24],
– early detection and prevalence of NaF uptake in the heart
and major arteries [4, 13, 18, 19, 24, 26, 31, 33, 35, 36],
– NaF uptake in vulnerable, high-risk, and ruptured plaques
[10, 12, 14–16, 20, 21, 34],
– influence of age, sex, and other factors on NaF uptake [5,
25–28, 30, 31],
– association between NaF uptake and cardiovascular risk
factors [9, 11, 23, 29, 32, 35, 38],
– NaF uptake and progression of atherosclerosis [37, 39].
Thus far, no intervention studies and no randomized clini-
cal trials aiming to reverse NaF-avid microcalcification have
been published.
Disease mechanisms and targeting
Irkle et al. demonstrated in carotid endarterectomy samples
that fluoride adsorbs to calcified areas in mineralized vas-
cular tissues and that NaF radioactivity is confined to calci-
fication and not to soft tissues. Furthermore, the NaF signal
depends on the surface area of calcification as NaF adsorbs
only to the outer layer of macrocalcifications in contrast to
microcalcifications which have a greater surface area and no
barriers to penetration of the tissues resulting in high levels
of NaF adsorption [17]. They confirmed this by autoradiog-
raphy, ex vivo μPET/μCT, and in vivo clinical PET/CT in
four patients scanned with NaF-PET/CT before carotid end-
arterectomy and concluded that “areas of 18F-NaF uptake
are reporting underlying microcalcifications, which are un-
detectable by CT” and further that NaF-PET/CT is “the only
currently available platform that can non-invasively detect
microcalcification in active unstable atherosclerosis” [17].
Fiz et al. evaluated NaF uptake in the infrarenal aorta of 64
patients with breast or prostate cancer and at least one CT-
visible (> 130 Hounsfield Units (HU)) calcification and
found average target-to-background ratios (TBRs) that were
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Fig. 1 PRISMA flow diagram
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uptake with no calcification (present in 86% of patients) and
decreased stepwise in plaques with light, medium, and
heavy density, defined by HU (Fig. 2) [24]. Similarly, Li L
et al. found in 32 patients with symptomatic coronary artery
disease a decline in maximal TBR from coronary
fibrocalcific via thincap with spotty calcifications to
thickcap mixed atheroma (from 1.42 via 1.32 to 1.28, re-
spectively) and to normal uptake (0.96) in fibrotic plaque
indicating that NaF uptake most likely localizes in the bor-
der zone of intensive calcification [15]. Zhang et al. ob-
served in eight patients undergoing carotid endarterectomy
significant positive correlation between NaF uptake and
calcification in histological sections of carotid plaques, a
negative correlation with smooth muscle staining, and no
correlation with carotid artery stenosis, HU value, or in-
flammation [22]. Partly in line with this, Kitagawa et al.
reported that per patient in 32 patients with known or
suspected coronary artery disease, TBRmax correlated pos-
itively with a logarithmically transformed coronary calcifi-
cation score, while per lesion, partially calcified plaque
showed higher TBRmax than calcified and non-calcified
plaque, i.e., 1.17 vs 1.00 vs 0.92 [14].
Early detection and prevalence of NaF uptake
Derlin et al. demonstrated (Table 1, Supplementary material)
in their 2010 study of 75 patients, referred to exclusion of
bone metastases, CT-calcification at 1930 sites in 84% of pa-
tients, NaF uptake in only 254 sites in 76% of patients, co-
localization of NaF accumulation, and CT-calcification in 223
areas of uptake (88%), and that only 12% of all arterial calci-
fication sites showed NaF uptake at least in some part [4]. In a
large retrospective study of oncologic patients, the same group
demonstrated that around 77% of lesions with marked NaF
uptake and only about 15% of lesions with FDG accumulation
were co-localized with arterial CT-calcification and that coin-
cident uptakes of both NaF and FDG were present in only
6.5% of 215 arterial lesions with radiotracer accumulation in
the carotid arteries, the aorta, and femoral arteries [36]. In the
third study of 409 oncologic patients, they focused in partic-
ular on linear NaF uptake in the femoral arteries and found this
in nearly 40% of patients, of which less than half had medial-
type linear CT-calcifications [35]. Moreover, they reported
CT-visible arterial plaques in carotids, aorta, right and left
iliac, left and right femoral arteries present at 3767 sites in
Fig. 2 Inverse relation between arterial wall uptake of NaF and CT-
visible calcification in the infrarenal aorta. High NaF uptake in aortic
lesion without CT-calcification (Hot spots = HS) and decreasing NaF
uptake with increasing density of CT-calcifications until same low NaF
uptake in high density plaques (Heavy plaques = HP) than in controls
(reproduced by permission from reference 24)
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83.1% of the patients aged 19.7–90.8 years, highest in the
abdominal aorta, followed by iliac arteries and thoracic aorta.
NaF uptake in femoral arteries correlated with multiple risk
factors and increased with the number of risk factors, from
9.7% of cases in their group with 0 risk factors to 64.1% in
their group with most, i.e., ≥ 5, risk factors [35].
Beheshti et al. demonstrated in a retrospective analysis of
51 oncologic patients a positive linear relation between NaF
uptake in the heart and aorta measured in five age groups (≤
40, 41–50, 51–60, 61–70 > 70 years) and noted that the ≤ 40
age group had a NaF uptake in the heart that was 57% of that
of the > 70 age group and in the aorta that was 65% of that
of the > 70 age group [26]. Li Y et al. reported in 61 patients
examined for bone lesions that NaF uptake was more frequent
in the aorta and femoral arteries than CT-calcification and vice
versa in the carotid and coronary arteries [33]. Fiz et al. dem-
onstrated in their study that early-stage CT-visible calcifica-
tion in the abdominal aorta has higher NaF uptake than the late
stage calcification [24]. Quirce et al. noted in two small studies
higher NaF uptake in patients with symptomatic than asymp-
tomatic carotid plaques [18, 19], while Kitagawa et al. in pa-
tients with coronary artery disease found slightly higher NaF
uptake in partially than non-calcified and calcified coronary
plaques [13]. Finally, Ferreira et al. observed similar NaF up-
take in the two sexes, despite the same age level, in the coro-
naries, carotids, and the aorta of patients with a 10-year risk of
fatal events ≥ 5% [31].
NaF uptake in vulnerable, high-risk, and ruptured
plaques
This has been studied in the coronary and carotids arteries
only (Table 2, Supplementary material). In a study of 40 pa-
tients with acute myocardial infarction, 40 patients with stable
angina who underwent invasive coronary angiography and 12
patients (of which 9 were evaluable) undergo who underwent
carotid endarterectomy for symptomatic carotid artery dis-
ease. Joshi et al. reported slightly, but significantly, higher
median NaF TBRmax (1.66 vs 1.24) in culprit lesions com-
pared with non-culprit carotid lesions [34]. Marked NaF up-
take was noted at all carotid plaque ruptures and plaques with
histologic evidence of active calcification, macrophage infil-
tration, apoptosis, and necrosis. Moreover, 18% of stable an-
gina pectoris patients had coronary plaques with focal NaF
uptake that was associated with more high-risk features on
intravascular ultrasound than those without uptake, which
made the authors conclude that NaF-PET/CT “is the first
non-invasive imagingmethod to identify and localize ruptured
and high-risk coronary plaque” [34]. Lee at al. reported from
coronary angiography in 51 patients that NaF uptake, mea-
sured as the maximal standardized uptake value (SUVmax) in
proximal coronary arteries, was higher in patients with
plaques considered high-risk than low-risk by intravascular
ultrasound (IVUS) or optical coherence tomography [12]. Li
et al. found in 32 patients, most of which with unstable angina,
that coronary NaF uptake was associated with high-risk
plaque features on IVUS, and that NaF uptake was highest
in lesions with the least calcification [15]. In 18 patients with
culprit carotid stenosis awaiting endarterectomy and 8 con-
trols without culprit carotid atheroma, Vesey et al. found,
using logarithmic SUVmean values, slightly, but significantly,
increased NaF uptake in “clinically adjudicated culprit
plaques” compared with asymptomatic contralateral plaques
which again was clearly higher than in controls (0.29 vs 0.23
vs 0.12). FDG uptake was increased in 7 of 16 culprit lesions
but with no difference between culprit vs contralateral plaques
or control patients [21]. Kitagawa et al. reported small, but
significant, differences in coronary NaF uptake among pa-
tients with and without later coronary events, which at 2-
year follow-up was 1 myocardial infarction, 3 cases of unsta-
ble angina, and 7 coronary revascularizations in 32 patients,
and concluded NaF-PET/CT has “the potential to detect high-
risk coronary disease and individual coronary lesions and pre-
dict future coronary events when combined with cardiac CT”
[14]. Marchesseau et al. observed in 10 patients examined 9–
24 days after ST-elevation myocardial infarct that TBRmax
was significantly higher (2.11 vs 1.36) in culprit than non-
culprit lesions and noted also that NaF uptake was clearly
higher in scarred than in remote myocardial tissue (0.87 vs
0.72) [16]. Finally, in an experimental study of samples of 17
culprit and 6 non-culprit carotid lesions from 23 stroke pa-
tients compared with 15 renal artery samples from healthy
kidney donors, Hop et al. found by micro-PET that average
NaF uptake (SUVmean) was equally high in culprit and non-
culprit lesions, but 5 times as high as in normal renal arteries,
and that only 10% of carotid CT-calcifications showed in-
creased NaF uptake, while only about 1/3 of NaF foci showed
calcification on CT [20].
Influence of age, sex, and other factors
A handful of studies have statistically demonstrated that arte-
rial wall microcalcification increases slightly, but significant-
ly, with age [5, 25, 26, 30].Most studies indicated a significant
correlation with age [5, 25, 30], and a single study recorded in
adults an increase by 75% from age ≤ 40 to age ≥ 70, albeit
with a wide scatter indicating that some young adults have
moderately high arterial wall NaF uptake, while a number of
old people have fairly low uptake [26]. There was no major
age difference between sexes with respect to arterial NaF up-
take as observed in more than just a single study [5, 26, 30,
31]. Derlin et al. reported a light association between carotid
NaF uptake and male sex in their oncologic patients [5],
whereas Blomberg et al. noted in healthy adults with an unfa-
vorable cardiovascular profile that female sex was an indepen-
dent factor of increased coronary artery NaF uptake [11]. In
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the only prospective study to date reporting FDG and NaF
uptake in healthy individuals, Blomberg et al. reported in-
crease in uptake with age in 89 healthy control subjects that
was less pronounced for FDG than NaF in that FDG uptake
increased with age only in the descending aorta, whereas cor-
relation of increase in NaF uptake and age was found in the
ascending aorta, aortic arch, descending aorta, and the coro-
nary arteries (Table 2, Supplementary material) [30]. Among
other factors, the same group examined in a single study of 18
angina pectoris patients and 20 healthy subjects scanned 45,
90, and 180 min after injection of NaF that the contrast be-
tween arterial wall NaF uptake and blood pool activity was
similar with 45 and 90 min acquisition and not improved after
180 min [27]. In another report, they demonstrated that blood
activity, injected dose, and the PET/CT system influence arte-
rial NaF uptake [28].
The interesting observation that arterial NaF uptake is in os-
seous exchange with bones was first reported by Derlin et al.,
who, in 608 femoral arterial segments of 304 patients (aged 20–
91 years) referred to exclusion of bone metastases, found an
inverse correlation between arterial NaF uptake and bone metab-
olism and that arterial mineral deposition increases with age,
while regional bone metabolism decreases (Fig. 3) [25].
Association between NaF uptake and cardiovascular
risk factors
From early on, the Derlin group showed in their large retro-
spective studies significant association between NaF uptake
in the carotid arteries and multiple risk factors including
age, male sex, hypertension, and hyperlipidemia, but not
history of smoking, diabetes, obesity, or cardiovascular
events [5] and in the femoral arteries correlation between
NaF uptake and the same risk factors plus diabetes and prior
cardiovascular events [25, 35] (Tables 1 and 3,
Supplementary material). Dweck et al. found that patients
with increased coronary NaF activity had higher rates of
prior cardiovascular events and angina and higher
Framingham Risk Score (FRS) [9]. Morbelli et al. demon-
strated in 80 oncologic patients a significant relationship
between NaF uptake in the carotid, subclavian, and iliac
arteries and the aorta and all risk factors except BMI, while
visible CT-calcification was dependent on age only
(Table 4, Supplementary material) [38]. Fiz et al. split their
77 patients with breast or pancreatic cancer without major
cardiovascular events and without statin therapy into three
risk groups according to their 10-year FRS, high, interme-
diate, and low, and found a clear association between de-
scending aorta and cardiac uptake of NaF and cardiovascu-
lar risk and suggested that the analysis approach with a
global metabolic score is superior to TBR values from se-
lected foci, since the global score includes NaF uptake in
both micro- and macrocalcification [29]. Blomberg et al.
reported a similar positive relationship between NaF uptake
in the thoracic aorta and FRS as between CT-visible calci-
fication and FRS, but not between FDG uptake and FRS
Fig. 3 Arterial mineral deposition increases with age, while regional bone
metabolism decreases. Coronal fused 18F-sodium fluoride PET/CT (a)
and non-fused PET of the thighs (b) of a 29-year-old woman with low
arterial mineral deposition (TBR 1.44) and high bone metabolism
(SUVmean 8.6). Coronal fused 18F-sodium fluoride PET/CT (c) and
non-fused PET of the thighs (d) of a 83-year-old woman showing high
arterial mineral deposition (TBR 2.18) and low bone metabolism
(SUVmean 6.7) (reproduced by permission from reference 25)
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(Fig. 4) [23]. In their prospective CAMONA trial, they dem-
onstrated in 89 healthy controls that coronary NaF uptake
increases linearly with the number of cardiovascular risk
factors and that female sex, age, and BMI are independent
factors of increased coronary NaF uptake (Table 4,
Supplementary material) [11]. Finally, Oliveira et al. report-
ed in 25 patients with hypertension, but without clinically
apparent cardiovascular disease, that 96%, 40%, and 64%
had increased NaF uptake in the aorta, the carotid, and cor-
onary arteries, respectively, and that the 14/25 of their pa-
tients, who had ≥ 5 risk factors, had an increased overall
uptake of NaF which was positively correlated with predict-
ed fatal cardiovascular risk SCORE and thoracic fat vol-
ume, but not with coronary calcium score [32].
NaF uptake and disease progression
Two of the 33 articles were reports on this topic. In 34 pa-
tients (aged 19–78 years, 18 women), Ishiwata et al. exam-
ined NaF uptake in the thoracic and abdominal aorta and in
the common iliac artery to see if NaF uptake could predict
progression of CT-calcification. A total of 182 sites with >
130 HU on CT and 96 hot spots, i.e., NaF-avid spots with <
130 HU at baseline were compared with CT at follow-up
after 1 year and later. They noted that baseline NaF uptake
did not correlate with CT-calcification in HUs or volume
after 1 year, but with change in calcification volume and
change in HU score. Novel CT macrocalcification was ob-
served after a mean of 1446 days in 19/96 of original NaF
hot spots without macrocalcifiation. Unfortunately, only CT
and not NaF imaging was repeated [39]. This was done in a
recent study by Li X et al. who analyzed 19 out of 34 mul-
tiple myeloma patients (aged 68 ± 9 years, 8 women), who
underwent both FDG and NaF imaging at an interval of 15 ±
4 months without in between intervention or important
change in medication. TBRmax was reported in three
groups of lesions, non-calcified (< 130 HU), mildly calci-
fied (130–399), and severely calcified (≥ 400). NaF and
FDG uptake was not correlated in non-calcified lesions,
but in mildly calcified (r = 0.7) and highly calcified lesions
(r = 0.4). FDG uptake was higher in non-calcified than cal-
cified lesions, the same pattern for NaF. NaF uptake in-
creased with increased plaque density, whereas FDG uptake
decreased. Inflammation and osteogenesis showed concor-
dant changes in 86% of non-calcified, 81% of mildly calci-











































Fig. 4 Positive relationship between arterial NaF uptake and
cardiovascular risk. Upper panel, left: Relationship between
cardiovascular risk factors and presence of NaF uptake in carotid
arteries. (reproduced with permission from reference 5). Upper panel,
right: Relationship between cardiovascular risk factors and presence of
NaF uptake in carotid arteries (reproduced with permission from
reference 35). Lower panel: 10-year Framingham risk score in relation
to quartiles of (a) thoracic aorta FDG activity, (b) thoracic aorta NaF
activity, and (c) thoracic aorta CT calcium burden. The risk is similar in
all quartiles of thoracic aorta FDG uptake, but increases linearly with each
increasing quartile of thoracic aorta NaF uptake (P < 0.001 for a linear
trend) and with each increasing quartile of thoracic aorta CT calcium
burden (P < 0.001 for a linear trend) (modified from reference 23)
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Discussion
Literature survey
The literature search produced nearly 3000 hits, one-third of
which were duplicates, whereas 1739 records were not includ-
ed because they met one or several exclusion criteria, while
finally eight additional papers were excluded for reasons stat-
ed in Fig. 1, leaving only 33 included articles. On average, less
than 4 new publications per year have been published since
the first report by Derlin et al. in 2010 [4], however, with
almost a tripling from the first to the last 3-year period. The
studies published so far varied in size, purpose, and method-
ology; several were retrospective analyses of patient popula-
tions examined originally for other purposes. Prospective
studies with distinct hypotheses, relevant design, proper ma-
terial of sufficient size, and reproducible methodologies were
in short supply. According to our subjective assessment, only
a little more than half of the studies were of high quality;
several were without hypothesis, had insufficient description
of materials and methods, lacked reference standards, and
sometimes made conclusions not sustained by the results.
Only few papers had a clearly stated, clinically relevant, and
patient-related purpose, and randomized controlled trials or
intervention studies have not been conducted so far. Due to
this diversity, our systematic literature search could not pro-
vide an answer to a particular scientific question; we were left
to summarize the information about NaF-PET in atheroscle-
rosis that the literature had provided until now and point to
important issues that remain unanswered.
Disease mechanisms and targeting
According to experimental literature, microcalcification, cate-
gorized by nodules < 50 μm, heralds the onset of arterial wall
mineralization triggered by cell death and inflammation
[40–42]. These nodules are too small to be detected by CT
imaging, but since they are the building stones of
macrocalcification, defined as nodules ≥ 50 μm [43] and can
be detected by NaF-PET imaging, they have become of sig-
nificant interest. In line with this, Irkle et al. highlighted the
spec i f i c i t y o f NaF up t ake , i t s con f i nemen t t o
microcalcification and not tissue, and pointed to NaF uptake
as a marker of nascent calcification and for testing of the
efficacy of anti-atherosclerotic interventions [17].
The literature tells us that FDG-avid foci in the arterial wall
are very common, with and without CT-calcification (Table 1,
Supplementary material), and something that ”waxes and
wanes” at short intervals [44] and therefore perhaps a natural
inflammatory response to arterial injury. In contrast, arterial
wall NaF uptake appears to be a more stable process localized
in, but not as part of, tissue, predominantly muscular necrosis.
In line with this, Marchesseau and co-workers demonstrated
by both PET/CTand PET/MRI imaging in patients with recent
acute myocardial infarction significantly higher (+ 45%) NaF
uptake in culprit than non-culprit coronary lesions and higher
(+ 14%) uptake in infarcted than non-infarcted myocardium
[16].
Early detection and prevalence of NaF uptake
The studies demonstrate localized, discrete, or diffuse abnor-
mal arterial wall uptake in men and women down to the age of
20 (Fig. 5) and that NaF uptake is not confined to identifiable
lesions, but varies considerably through each arterial segment
(Fig. 6) [23, 30, 36]. Studies in a metabolic syndrome pig
model suggest that increased coronary uptake of NaF is pres-
ent in the very early-stages of atherosclerosis since fatty cor-
onary streaks of these swine pick up NaF [45]. Pathologic
studies have demonstrated that almost every North
American child over the age of 3 years has some degree of
aortic fatty streaks [46] and that by the age of 15–19 years,
fatty streaks occupy about 25% of the aortic intima in the
thoracic and abdominal aorta and that they increase in the
abdominal aorta to occupy nearly 40% at the age of 34–40
years [47]. There is indication that fatty streaks may translate
into raised lesions of atherosclerosis (a collective term for
fibrous plaques and associated complications) and that coro-
nary events become frequent in a population when the average
extent of coronary raised lesions in middle-aged persons ap-
proaches 30% of the coronary intimal surface [47].
Considering the apparent lack of difference in arterial NaF
uptake in women and men [5, 26, 30, 31], it is suggestive that
in age groups 15–19 to 30–34 years, fatty streaks have been
found to be equally frequent in the coronary arteries of men
and women, but that women have about one-half of the extent
of raised lesions at all ages. Furthermore, the thoracic aorta is
highly susceptible of fatty streaks, but not to raised lesions,
and that abdominal aorta of women has more extensive fatty
streaks than that of men, but an equal extent of raised lesions
[47].
NaF uptake in vulnerable, high-risk, and ruptured
plaque
Several authors have with different quantification algorithms
demonstrated higher NaF uptake in vulnerable, high-risk, and
ruptured plaques, which may not be, as often claimed [10], a
means to accurately identify high-risk plaques or predict fu-
ture cardiovascular events in individual patients (Table 2,
Supplementary material). To be of clinical use, identification
of individual high-risk plaques and prediction of coming
events should be possible in single patients with a fairly high
probability as for instance one of 85% or higher, which has so
far not been demonstrated. Moreover, the search for presumed
vulnerable plaques may not be as useful as often stated
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because, as suggested by Arbab-Zadeh and Fuster, a state of
generalized vulnerability may be more important overall than
characterizing the individual sites of vulnerability in the indi-
vidual patient, the reasons being that plaque rupture often
occurs without clinical symptoms, plaque morphology chang-
es over a few months, and plaque rupture frequently occurs
apart from the culprit lesions [48]. These are insightful per-
spectives and suggest at least three major concepts. (1)
Generalized vulnerability may be the earliest molecular calci-
fication, preceding microcalcification, and should be studied
in preclinical models to determine the basis. Molecular calci-
fication would almost certainly occur before subclinical
plaque rupture. (2) The natural course of focal NaF uptake
must be studied prospectively to determine whether these sites
become sufficiently vulnerable to trigger acute myocardial
infarction requiring coronary intervention, e.g., stenting.
Fig. 5 Abnormal arterial wall
NaF uptake has been observed
down to the age of 20 and is most
often present in the absence of
CT-calcification. Upper panel:
NaF uptake (right) in the thoracic
aorta (yellow arrows) of a 24-
year-old symptom-free male with
no CT-visible calcification (left).
Lower panel: 69-year-old male
with angina pectoris and CT-
visible calcification in the left an-
terior descending coronary artery
and the descending thoracic aorta
(white arrows, left) and NaF up-
take in the same arteries, incon-
gruent with CT-calcifications and
with far greater circumferential
extension in the aorta (yellow ar-
rows, right) (images frommaterial
of references 23 and 30)
Fig. 6 NaF uptake is often not confined to identifiable lesions, but varies
through each arterial segment. Variation in FDG (red areas) and NaF
(green areas) uptake through the entire aorta. The red and green dots are
blood background subtracted SUVmax values from horizontal slices of
3.75 mm thickness. Note the outspoken disconcordance and the generally
higher FDG uptake in the thoracic part (to the left) and generally higher
NaF uptake in the abdominal part of the aorta (to the right) (from the
material of reference 23)
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This would add further clarity to the prospective study of Joshi
et al. [34]. (3) Continued use of artery-specific 18F-NaF im-
aging with coronary CT angiography [45, 49, 50] and a more
high throughput global scoring system [26] not requiring ra-
diopaque contrast infusion may be highly relevant for coro-
nary artery risk stratification and prospective studies of thera-
peutic interventions [51].
Influence of age, sex, and other factors on NaF uptake
Most studies examining the association between arterial
uptake of NaF and age found a modest, but statistically
significant, increase with age which was more pronounced
in cardiovascular patients, albeit with a substantial varia-
tion over the entire range of adult ages (Fig. 7) (Table 3,
Supplementary material). Across methods, there was the
mentioned finding that men and women of the same age
have roughly the same degree and frequency of abnormal
arterial wall NaF uptake [5, 26, 30, 31]. The reason for
this is unknown, except for the observations by McGill
and co-workers suggesting a difference in time between
women and men in the transition from micro- to
macrocalcification [47]. Finally, there may be an “osseous
exchange” between NaF uptake and bones, meaning that
patients with osteoporosis may have a diminished tenden-
cy to accumulate NaF in their arteries [25].
Association between NaF uptake and cardiovascular
risk factors
The general finding was a positive correlation between NaF
uptake and cardiovascular risk in all examined parts of the
arterial system (coronary arteries, the aorta and the carotid,
iliac and femoral arteries), a correlation that was significant,
but with a wide scatter. No one has investigated the potential
superiority or non-inferiority of NaF-PET with regard to risk
prediction. A significant association was present in patients
with atherosclerosis of varying degrees and patients with on-
cologic diseases as well as healthy asymptomatic control sub-
jects, albeit with a slightly steeper slope in patients. A simi-
larly significant relationship was not found between FDG up-
take and cardiovascular risk; in fact, in some studies, such
association could not be proven [23, 31].
NaF uptake and disease progression
There was a complete lack of longitudinal studies using repeat
NaF-PET imaging to investigate the development of NaF-avid
arterial wall uptake. A few studies compared initial NaF im-
aging results with clinical findings at 1–2 years of follow-up,
but did not repeat NaF-PET/CT imaging. They reported
higher NaF uptake in non-calcified than calcified plaques at
baseline and that initial NaF uptake did not correlate with CT-
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Fig. 7 NaF uptake increases with age, the more so in patients, but with a
wide scatter. NaF uptake in the heart and thoracic aorta of healthy control
subjects and angina pectoris patients as a function of age. Note the steeper
slope in angina pectoris patients. All correlations were statistically
significant, but with a large scatter indicating that among both healthy
individuals and cardiac patients, there are some individuals with very low
and some with very high NaF uptake (from the CAMONA material of
references 11 and 23)
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Methodology
Each center used approximately the same methodology in all
their studies. Across centers and institutions, there was great
diversity in terms of equipment and acquisition protocol and
especially with regard to analysis and quantification methods
making direct comparisons virtually impossible. A minority of
studies mentioned or listed medication and not a single one ex-
amined effects of medication on NaF uptake. There was no con-
sensus on how tomeasure arterial wall NaF uptake. Themajority
of centers used some kind of TBR to quantify NaF uptake, i.e.,
an approach with certain disadvantages [16, 27], other used sub-
traction of blood background, most often from the superior vena
cava or the right atrium, since the recorded NaF concentration is
lower here than elsewhere in the venous system, probably de-
pending on cross-talk from NaF uptake in close by bones [28,
30]. A more in-depth discussion of quantification methods is
beyond the scope of this article. Instead, readers are referred to
articles dealing with such topic [16, 26–29, 52–57].
Limitations
This review is based on a systematic literature search covering
the years 2010–2018, meaning that the 2019 literature is not
included and debated. A number of circumstances make the
literature on NaF-PET in arteriosclerosis so heterogeneous
that it is not possible to draw any firm conclusions. Among
these circumstances were differences in image acquisition and
acquisition timing, processing, and measures of arterial wall
uptake, without and with background correction. Moreover,
there was a frequent lack of specific aims for the conducted
studies, and shortcomings of the PET technique with its lim-
ited spatial resolution were by some considered overcome or
not mentioned at all. Nonetheless, a number of observations,
listed below, may hold true, whereas other questions remain
unanswered.Most 2019 papers onNaF-PET imaging focus on
unstable or what is designated vulnerable plaque morphology
and detection in predominantly the coronary arteries often
employing advanced methodologies [49, 56, 58–63]. In
August 2019, the first study on the efficacy of therapy judged
by NaF-PET imaging appeared. In a randomized trial of pa-
tients with high-risk coronary plaque, there was no effect of
dual antiplatelet therapy with ticagrelor in terms of a reduction
in plasma tropinin concentration or NaF uptake in the proxi-
mal parts of the coronary arteries [50]. The study is a good
example of the potential of NaF-PET combined with CT an-
giography to track the effects of therapeutic intervention on
focal NaF uptake to phenotype coronary plaque.
The authors of this review consider measures of focal NaF
uptake in the coronary arteries as very promising, but we urge
caution, mainly because it is challenging to detect and mea-
sure by PET the NaF uptake in anything but the larger, most
proximal parts of the coronary arteries [57, 64], which may
not be representative for the total cardiac atherosclerotic bur-
den. Thus, we share the opinion of authors Arbab-Zadeh and
Fuster that the atherosclerotic burden rather than the “vulner-
able plague” should be the target of molecular atherosclerosis
imaging [48, 65, 66]. To discuss these important issues in
detail is not possible within the frame of this review.
Fig. 8 Hypothetical illustration of the possible time- and age-related re-
lationship among arterial wall FDG uptake, NaF uptake, and CT-visible
calcification. The courses in childhood and very high ages are unknown.
FDG uptake may be a frequently occurring repetitive process throughout
life in response to minor or major arterial injuries [44]. By targeting
microcalcification [17], NaF appears to be a more persistent marker of
early phase atherosclerosis [4, 15, 24, 30, 36] and, through surface ad-
sorption to macrocalcification [17], to a lesser degree also of still ongoing
calcification in CT-visible calcifications [24]. The three processes follow
different patterns, a slow and protracted increase of FDG uptake, a sim-
ilarly early in life occurring NaF uptake that tends to persist and increase
for some age decades until it decreases when macrocalcification grows
and stabilizes, and finally, and in contrast, CT-detectable calcification that
appears later in life and continues with aging (illustration byDr. Reza Piri,
Dept. of Nuclear Medicine, Odense University Hospital, Odense,
Denmark)
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Information gleaned from the literature
Despite reservations and shortcomings, the following infor-
mation could be gleaned from the existing literature. In addi-
tion, we have made a hypothetical figure illustrating the po-
tential time course of FDG-, NaF-, and CT-detectable arterial
wall changes (Fig. 8).
& NaF is a highly specific and sensitive PET tracer targeting
microcalcification, often due to tissue necrosis but not
being a component of natural arterial wall tissue.
& NaF uptake indicates and represents active, ongoing
microcalcification.
& NaF uptake is often present and higher in areas without
than with CT-calcification and coincides only sporadically
with arterial foci of abnormal FDG uptake.
& NaF uptake associated with CT-calcification is surface lo-
cated and less when the density of CT-calcification is high.
& NaF uptake is higher in vulnerable, high-risk, and ruptured
plaques, but cannot identify these or predict events in in-
dividual patients with a high probability.
& NaF uptake increases slightly with age, but with a large
variability, indicating that some subjects are more inclined
to develop atherosclerosis than others.
& NaF uptake does not exhibit the same 10-year delay in
women compared with men as observed with regard to
CT-visible macrocalcification and cardiovascular events.
Answers to the following questions have not been provided
thus far:
& Do fatty streaks in human arteries accumulate NaF? If so,
what component of streaks does so?
& Does NaF- (and/or FDG-) avid microcalcification prog-
ress to CT-visible macrocalcification in the natural pro-
gression of atherosclerosis?
& In which compartment of the arterial wall does
microcalcification first appear?
& Can NaF-avid microcalcification be diminished or
abolished by medical therapy or other types of interven-
tion? This is especially important because statin therapy
promotes macrocalcification [67].
& If so, should therapy be initiated before a certain critical
time point to be effective?
& Is atherosclerotic disease burden in the arterial system a
better predictor of cardiovascular events than uptake in
selected high-risk or vulnerable plaques?
& Is atherosclerotic burden by NaF-PET in individual
patients equal or superior to common risk factors with
regard to prediction of future cardiovascular events?
Conclusion
The available literature onNaF-PET imaging of atherosclerosis is
limited, heterogeneous, and diverging with regard to scope, size,
methodology, and studied arterial segment, and devoid of long-
term follow-up studies and intervention trials. Early atheroscle-
rosis is characterized by arterial wall microcalcification that is
detectable and quantifiable by means of NaF-PET/CT probably
years or decades before it presumably gives rise to CT-visible
macrocalcification, which may take up NaF on its surface, but
with decreasing intensity the more dense the calcification. NaF is
a highly specific and very sensitive tracer with high affinity for
active, ongoing molecular microcalcification that appears to be
due to tissue necrosis. NaF-PET is the only existing in vivo mo-
dality that can detect and quantify the active atherosclerotic pro-
cess. NaF uptake correlates consistently with cardiovascular risk
factors, suggesting that NaF-PET imaging alone or in conjunc-
tion with selected risk factors is capable of providing a better,
much earlier, andmore accurate assessment of the arteriosclerotic
burden in the body than what can be achieved with other tech-
niques. Future research should document translation of NaF-avid
microcalcification into CT-visible macrocalcification and assess
to what extent and when anti-atherosclerotic intervention can
diminish or abort the arteriosclerotic disease process.
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